XenoPort Company Profile (NASDAQ:XNPT)

About XenoPort

XenoPort logoXenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company's segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson's disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: XNPT
  • CUSIP: 98411C10
Key Metrics:
  • Previous Close: $7.02
  • 50 Day Moving Average: $6.71
  • 200 Day Moving Average: $5.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.71
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 1.94
Additional Links:
Companies Related to XenoPort:

Analyst Ratings

Consensus Ratings for XenoPort (NASDAQ:XNPT) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $7.00 (0.28% downside)

Analysts' Ratings History for XenoPort (NASDAQ:XNPT)
DateFirmActionRatingPrice TargetDetails
5/24/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
5/6/2016Cowen and CompanyReiterated RatingHoldView Rating Details
1/19/2016Credit Suisse GroupInitiated CoverageUnderperform$4.00View Rating Details
9/15/2015Royal Bank Of CanadaReiterated RatingBuy$10.00View Rating Details
(Data available from 2/19/2015 forward)


Earnings History for XenoPort (NASDAQ:XNPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2016Q116($0.21)($0.23)$14.24 million$14.12 millionViewN/AView Earnings Details
2/25/2016Q415($0.31)($0.21)$13.74 million$14.07 millionViewListenView Earnings Details
11/4/2015Q315($0.38)($0.38)$11.77 million$11.40 millionViewN/AView Earnings Details
8/5/2015Q215($0.32)($0.39)$9.77 million$8.60 millionViewN/AView Earnings Details
5/6/2015Q115($0.29)($0.33)$8.50 million$7.10 millionViewN/AView Earnings Details
2/19/2015Q414($0.34)($0.28)$7.10 million$7.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.36)$0.13$6.30 million$31.10 millionViewN/AView Earnings Details
8/6/2014Q214($0.33)($0.31)$4.38 million$5.30 millionViewN/AView Earnings Details
5/8/2014Q114($0.32)($0.36)$3.86 million$3.40 millionViewListenView Earnings Details
2/20/2014Q413($0.45)($0.40)$3.35 million$2.90 millionViewListenView Earnings Details
11/4/2013Q313($0.51)($0.39)$3.03 million$2.52 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.53)($0.51)$1.74 million$2.10 millionViewN/AView Earnings Details
4/24/2013Q1 2013($0.43)($0.50)$1.20 million$4.59 millionViewN/AView Earnings Details
3/11/2013Q4 2012($0.42)$0.07$1.02 million$0.49 millionViewN/AView Earnings Details
10/24/2012Q312($0.43)($0.41)$2.26 million$0.40 millionViewN/AView Earnings Details
8/7/2012($0.39)($0.22)ViewN/AView Earnings Details
5/2/2012($0.22)($0.26)ViewN/AView Earnings Details
2/14/2012($0.39)($0.48)ViewN/AView Earnings Details
11/2/2011($0.44)($0.55)ViewN/AView Earnings Details
8/3/2011($0.23)$0.55ViewN/AView Earnings Details
5/5/2011($0.49)($0.49)ViewN/AView Earnings Details
2/16/2011($0.62)($0.47)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for XenoPort (NASDAQ:XNPT)
Current Year EPS Consensus Estimate: $-0.49 EPS
Next Year EPS Consensus Estimate: $-0.42 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.26)($0.26)($0.26)
Q2 20161($0.24)($0.24)($0.24)
Q3 20161($0.18)($0.18)($0.18)
Q4 20161($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)


Dividend History for XenoPort (NASDAQ:XNPT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for XenoPort (NASDAQ:XNPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/19/2016James E FlynnInsiderBuy20,973$3.99$83,682.27View SEC Filing  
2/12/2016James E FlynnInsiderBuy4,883,761$3.87$18,900,155.07View SEC Filing  
1/20/2016James E FlynnInsiderBuy346,417$4.09$1,416,845.53View SEC Filing  
9/1/2015Ronald W BarrettCEOSell12,500$7.00$87,500.00View SEC Filing  
7/15/2015Ronald W BarrettCEOSell12,500$7.20$90,000.00View SEC Filing  
7/13/2015Ronald W BarrettCEOSell12,500$7.00$87,500.00View SEC Filing  
5/11/2015Wendall WierengaDirectorBuy5,000$5.63$28,150.00View SEC Filing  
12/8/2014Gregory T BatesSVPSell14,166$8.35$118,286.10View SEC Filing  
12/8/2014Ronald W BarrettCEOSell7,015$8.36$58,645.40View SEC Filing  
12/5/2014Gianna M BoskoSVPSell60,000$8.45$507,000.00View SEC Filing  
9/9/2014Gregory T BatesSVPSell5,612$5.26$29,519.12View SEC Filing  
6/3/2014John Gordon FreundDirectorBuy12,500$3.93$49,125.00View SEC Filing  
5/27/2014Cathy FriedmanDirectorBuy2,600$3.92$10,192.00View SEC Filing  
5/23/2014John Gordon FreundDirectorBuy15,000$3.73$55,950.00View SEC Filing  
5/23/2014Ronald W BarrettCEOBuy2,600$3.75$9,750.00View SEC Filing  
5/15/2014Paul BernsDirectorSell2,500$3.66$9,150.00View SEC Filing  
4/24/2014Paul BernsDirectorSell2,500$4.30$10,750.00View SEC Filing  
6/14/2013Gregory T BatesSVPSell7,500$5.35$40,125.00View SEC Filing  
5/22/2013Ernest MarioDirectorBuy20,000$5.49$109,800.00View SEC Filing  
8/9/2012Ernest MarioDirectorBuy10,000$8.50$85,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for XenoPort (NASDAQ:XNPT)
News IconCarmot Therapeutics Appoints Aetna Wun Trombley, Ph.D. ... (NASDAQ:XNPT)
www.biomedreports.com - August 16 at 11:44 AM
News IconCarmot Therapeutics Appoints Aetna Wun Trombley, Ph.D. to the Board of Directors and Elena Viboch as Director of Business Development and Operations (NASDAQ:XNPT)
www.cbs58.com - August 16 at 11:44 AM
streetinsider.com logoArbor Pharma Announces Results of XenoPort (XNPT) Tender Offer - StreetInsider.com (NASDAQ:XNPT)
www.streetinsider.com - July 5 at 7:58 PM
biz.yahoo.com logoXENOPORT INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure t (NASDAQ:XNPT)
biz.yahoo.com - July 5 at 4:54 PM
publicnow.com logoArbor Pharmaceuticals Completes Successful Tender Offer for Shares of XenoPort (NASDAQ:XNPT)
www.publicnow.com - July 5 at 6:51 AM
kcregister.com logoFast Moving Stocks: Xenoport, Inc. (NASDAQ:XNPT), Kite Pharma, Inc. (NASDAQ:KITE), EMC Corporation (NYSE:EMC ... - KC Register (NASDAQ:XNPT)
www.kcregister.com - July 1 at 11:03 AM
streetinsider.com logoXenoPort (XNPT) Enters MOU Over Pending Merger; Agrees to Make Additional Disclosures (NASDAQ:XNPT)
www.streetinsider.com - June 28 at 8:20 PM
News IconInvestor News: Lawsuit against Buyout of XenoPort, Inc. (NASDAQ:XNPT) filed - GroundReport (NASDAQ:XNPT)
www.groundreport.com - June 27 at 8:06 PM
kcregister.com logoXenoport, Inc. (NASDAQ:XNPT) went up 0.29%: Chiasma, Inc. (NASDAQ:CHMA), United Technologies Corporation ... - KC Register (NASDAQ:XNPT)
www.kcregister.com - June 24 at 8:21 PM
istreetwire.com logoAnalytical Report: Xenoport, Inc. (NASDAQ:XNPT) - iStreetWire (NASDAQ:XNPT)
istreetwire.com - June 23 at 9:10 PM
marketwatch.com logoWhat Brexit Vote Could Mean for U.S. 2016 Election (NASDAQ:XNPT)
www.marketwatch.com - June 22 at 6:52 PM
News IconLawsuit for Investors in XenoPort, Inc. (NASDAQ:XNPT) in Effort to Halt Acquisition Filed - Digital Journal (NASDAQ:XNPT)
www.digitaljournal.com - June 22 at 5:29 AM
4-traders.com logoLawsuit for Investors in XenoPort, Inc. (NASDAQ:XNPT) in Effort to Halt Acquisition Filed (NASDAQ:XNPT)
www.4-traders.com - June 21 at 7:48 PM
moodys.com logoArbor Pharmaceuticals, LLC -- Moody's Assigns B1 CFR to Arbor Pharmaceuticals; Stable Outlook (NASDAQ:XNPT)
www.moodys.com - June 21 at 12:08 PM
finance.yahoo.com logoArbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act Waiting Period (NASDAQ:XNPT)
finance.yahoo.com - June 16 at 6:30 AM
News IconInvestor News: Buyout of XenoPort, Inc. (NASDAQ:XNPT) faces Investigation over possible Breaches Of Fiduciary Duties (NASDAQ:XNPT)
www.groundreport.com - June 7 at 8:41 PM
finance.yahoo.com logoSurging Earnings Estimates Signal Good News for Xenoport (XNPT) (NASDAQ:XNPT)
finance.yahoo.com - June 6 at 8:55 AM
fool.com logoWhy Xenoport, Inc. Stock Jumped 61.1% in May (NASDAQ:XNPT)
www.fool.com - June 4 at 9:04 AM
News IconTakeover of XenoPort, Inc. (NASDAQ:XNPT) Under Investigation for Investors Concerning Potential Wrongdoing (NASDAQ:XNPT)
www.digitaljournal.com - June 3 at 9:09 PM
finance.yahoo.com logoSHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of XenoPort, Inc. - XNPT (NASDAQ:XNPT)
finance.yahoo.com - May 27 at 10:13 PM
finance.yahoo.com logoXENOPORT SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Xenoport, Inc. (XNPT) Over the Proposed Sale of the Company to Arbor Pharmaceuticals, LLC (NASDAQ:XNPT)
finance.yahoo.com - May 26 at 4:16 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie (NASDAQ:XNPT)
finance.yahoo.com - May 26 at 9:30 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning Whether the Sale of XenoPort, Inc. to Arbor Pharmaceuticals, LLC for $7.03 Per Share is Fair to Shareholders -- XNPT (NASDAQ:XNPT)
finance.yahoo.com - May 25 at 3:12 PM
streetinsider.com logoArbor Pharma to Acquire XenoPort (XNPT) for $7.03/Share; Deal Valued at ~$467M (NASDAQ:XNPT)
www.streetinsider.com - May 25 at 11:44 AM
News IconAiling XenoPort (XNPT) Lifted on Buyout Announcement (NASDAQ:XNPT)
www.economiccalendar.com - May 25 at 11:44 AM
bizjournals.com logoArbor Pharmaceuticals to buy XenoPort for $467M (NASDAQ:XNPT)
www.bizjournals.com - May 25 at 11:44 AM
bidnessetc.com logoXenoPort Inc (XNPT) Stock Skyrockets on Arbor Merger Agreement (NASDAQ:XNPT)
www.bidnessetc.com - May 25 at 11:44 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of XenoPort, Inc. and Encourages Investors to Contact the Firm for Additional Information (NASDAQ:XNPT)
finance.yahoo.com - May 24 at 10:10 PM
capitalcube.com logoETF’s with exposure to XenoPort, Inc. : May 24, 2016 (NASDAQ:XNPT)
www.capitalcube.com - May 24 at 3:50 PM
bizjournals.com logoArbor Pharmaceuticals to buy XenoPort for $467 million (NASDAQ:XNPT)
feeds.bizjournals.com - May 24 at 2:57 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of XenoPort Inc. - XNPT (NASDAQ:XNPT)
finance.yahoo.com - May 24 at 12:31 PM
smarteranalyst.com logoMonday's Market Insights: Relypsa Inc (RLYP), Seadrill Ltd (SDRL), Nanosphere, Inc. (NSPH), XenoPort, Inc. (XNPT) - Smarter Analyst (NASDAQ:XNPT)
www.smarteranalyst.com - May 24 at 12:18 PM
kcregister.com logoHealthcare Unusual Volume: Xenoport, Inc. (NASDAQ:XNPT), Cellectar Biosciences, Inc. (NASDAQ:CLRB), Rock ... - KC Register (NASDAQ:XNPT)
www.kcregister.com - May 24 at 12:18 PM


What is XenoPort's stock symbol?

XenoPort trades on the NASDAQ under the ticker symbol "XNPT."

Where is XenoPort's stock going? Where will XenoPort's stock price be in 2017?

2 brokerages have issued 12-month price targets for XenoPort's stock. Their forecasts range from $7.00 to $7.00. On average, they expect XenoPort's stock price to reach $7.00 in the next year.

When will XenoPort announce their earnings?

XenoPort is scheduled to release their next quarterly earnings announcement on Wednesday, August, 3rd 2016.

What are analysts saying about XenoPort stock?

Here are some recent quotes from research analysts about XenoPort stock:

  • According to Zacks Investment Research, "XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of existing drugs. " (7/6/2016)

  • Jefferies Group LLC analysts commented, "XNPT reported Q1 loss/share of $0.23 (vs -$0.26 JEFe). The narrower than projected Q1 loss was driven by solid Horizant sales of $13.7M (+106% Y/ Y; +15% vs JEFe) despite a one week destock in wholesaler inventory. Ex one outlier, the Q1 Horizant performance exceeded consensus by 3%. We continue to view mgt’s FY16 Horizant sales guidance of $61-65M as eminently achievable." (5/6/2016)

How do I buy XenoPort stock?

Shares of XenoPort can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of XenoPort stock cost?

One share of XenoPort stock can currently be purchased for approximately $7.02.

XenoPort (NASDAQ:XNPT) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for XenoPort (NASDAQ:XNPT)

Earnings History Chart

Earnings by Quarter for XenoPort (NASDAQ:XNPT)

Dividend History Chart

Dividend Payments by Quarter for XenoPort (NASDAQ:XNPT)

Last Updated on 2/19/2017 by MarketBeat.com Staff